Researchers examined 39 patients treated with FMT for recurrent C. diff infection at an academic medical center between July 2010 and January 2016. They collected information on FMT-related complications, recurrent C. diff and short-and long-term adverse events via telephone interviews using a questionnaire. The follow-up period ranged between three months and 68 months.
Here are five insights:
1. The primary cure rate — no recurrence of C. diff within eight weeks after one infusion with donor feces — was 82 percent.
2. Of the remaining seven patients with recurrent C. diff after FMT, antibiotic therapy alone cured four patients and repeat FMT cured three patients.
3. Perioperative complications occurred in five patients, including fecal regurgitation or vomiting.
4. One patient died one week after FMT due to pneumonia. Researchers could not exclude this incident’s relation with FMT.
5. No long-term side effects were reported.
More articles on healthcare quality:
How does hospital patient room design affect HAI rates?
Cancer cases, deaths worldwide in 2015: 5 findings
How one device can decrease the prevalence of postoperative delirium
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
